secwatch.observer — SEC 8-K summary
======================================

Issuer:     Perspective Therapeutics, Inc. (CATX)
CIK:        0000728387
Form:       8-K
Filed at:   2026-10-08T10:28:19+00:00
Accession:  0001193125-26-417384
Event type: regulatory
Sentiment:  positive
Materiality: 0.60
Item codes: 8.01, 9.01
LLM model:  deepseek-v4.1-flash:cloud@v2

Perspective Therapeutics wins FDA Fast Track for PSV359 in FAP-positive solitary fibrous tumors
--------------------------------------------------------------------------------

- FDA granted Fast Track Designation for [212Pb]PSV359 in adults with locally advanced unresectable and/or metastatic FAP-positive solitary fibrous tumors (SFTs).
- PSV359 is an investigational FAP-targeted alpha-particle therapy using the alpha-emitting isotope 212Pb, now in an ongoing Phase 1/2a study in advanced FAP-positive solid tumors.
- Fast Track may bring more frequent FDA interactions and eligibility for rolling review, Accelerated Approval, or Priority Review if criteria are met.
- CMO Markus Puhlmann noted no approved therapies specifically target FAP-alpha; imaging of FAP expression allows patient selection for targeted alpha therapy.
- CEO Thijs Spoor called the designation an important step for the broader PSV359 program; SFT patients with unresectable/metastatic disease have limited options.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/728387/000119312526417384/0001193125-26-417384-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/728387/000119312526417384/catx-20261008.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-417384

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer